Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2026)

Caris Life Sciences' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $525.3 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $525.3 million in Q1 2026; TTM through Mar 2026 was $525.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $506.0 million, down 4.4% from the prior year.
• Total Non-Current Liabilities rose to $525.3 million in Q1 2026 per CAI's latest filing, from $506.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $529.3 million in Q4 2024 and bottomed at $502.2 million in Q2 2025.
• The 3-year median for Total Non-Current Liabilities is $506.2 million (2025), against an average of $513.8 million.
• Biggest YoY gain for Total Non-Current Liabilities was 4.4% in 2025; the steepest drop was 4.4% in 2025.
• Year by year, Total Non-Current Liabilities stood at $529.3 million in 2024, then declined by 4.4% to $506.0 million in 2025, then gained by 3.82% to $525.3 million in 2026.
• Per Business Quant, the three latest CAI Total Non-Current Liabilities figures stand at $525.3 million (Q1 2026), $506.0 million (Q4 2025), and $506.2 million (Q3 2025).